1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
InnSuites Hospitality Trust said NYSE American accepted its compliance plan and granted a plan period through December 24, 2027. The Trust is not currently in compliance with NYSE American continued listing standards, but its listing continues under the extension, and staff could start delisting proceedings if the Trust does not meet the standards or make progress under the plan.
NYSE American notice received September 10, 2026; plan period runs through December 24, 2027
Trust increased stockholders' equity by $3 million on August 19, 2026, as one step toward compliance
Consolidated net income for the Fiscal First Quarter was $74,702, up 48% from the prior year quarter
Filing states there is no assurance the Trust will regain compliance or complete any proposed transaction
FatPipe appointed Kanishka Ragula, age 25, as Chief Financial Officer and Principal Accounting Officer effective September 11, 2026, replacing Eric Sherb, who ceased serving in those roles on the same date. The filing says Sherb's departure was not the result of any disagreement with the company and that he will consult for FatPipe during the transition. Ragula's family relationship to the CEO and Chairman is disclosed, which shareholders may weigh when assessing the appointment.
Eric Sherb ceased serving as CFO and Principal Accounting Officer effective September 11, 2026, and will continue as a consultant.
Kanishka Ragula, age 25, was appointed CFO and Principal Accounting Officer effective September 11, 2026; he had been Director of Finance since September 2025.
Ragula will receive an annual base salary of $175,000 plus an equity grant to be approved by the board at the annual meeting.
Ragula is the son of CEO and Chairman Ragula Bhaskar, Ph.D., and of President, CTO and director Sanchaita Datta.
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
BOXABL concluded the employment of CFO Martin Costas effective September 11, 2026, and appointed Larry King as CFO effective September 14, 2026. The company also said Heather Clayton will become Chief Accounting Officer beginning September 28, 2026. The filing says Costas's departure was not due to any disagreement with the company on operations, policies, or practices.
Martin Costas's employment as CFO concluded effective September 11, 2026; the filing states no disagreement with the company was the reason.
Larry King, 65, a Certified Public Accountant, was appointed CFO and principal financial and accounting officer effective September 14, 2026, with an annual salary of $300,000.
Heather Clayton will begin as Chief Accounting Officer on September 28, 2026, with an annual salary of $250,000.
Offer letters for King and Clayton are filed as Exhibits 10.1 and 10.2.
Addus HomeCare's subsidiary agreed on September 12, 2026 to acquire the personal care business of AccentCare outside New York for $275 million in cash, subject to adjustments. The company expects the deal to add about $280 million in annualized revenue, which it says would be roughly a 19% increase to its revenue base, and plans to fund it through its revolver and cash on hand. Closing depends on regulatory approvals and the Hart-Scott-Rodino waiting period, so shareholders will not see the deal's effect until it closes.
Purchase price is $275 million in cash, subject to working capital and other customary adjustments.
Company expects about $280 million in annualized personal care revenue, which its CEO describes as roughly a 19% increase to revenue.
Acquired operations serve an average daily census of about 13,700 customers across a 10-state footprint.
Closing requires regulatory approvals and the expiration of the HSR waiting period; the deal has no financing condition and no termination or reverse termination fee.
NextEra Energy and Dominion Energy issued a joint press release on September 14, 2026, announcing an enhanced Virginia benefits package under their pending Merger Agreement. The package proposes doubling $10 per month residential bill credits from two years to four years, a $100 million increase to the EnergyShare low-income assistance program, and new jobs and a Richmond office tower. The companies say these commitments depend on approval and closing of the combination, which they expect in the second half of 2027, so the filing does not change the financial results of either company.
Residential bill credits of $10 per month would run four years instead of two.
EnergyShare low-income assistance would increase by $100 million through 2038.
NextEra plans 600 new jobs in Virginia and a $100 million workforce development fund; the companies expect the transaction to close in the second half of 2027.
Boxlight received a Nasdaq Hearings Panel decision on September 2, 2026 that it has regained compliance with the $2.5 million stockholders' equity requirement and may continue listing on Nasdaq. The Panel also imposed a one-year monitoring period, so any future Nasdaq rule noncompliance could lead directly to a delisting determination without a cure period.
Panel decision dated September 2, 2026 found compliance with the $2,500,000 stockholders' equity rule (Rule 5550(b)(1)).
Compliance plan relied on a Series D preferred financing: $4.8 million raised in Tranche One on August 5, 2026, with about $6.6 million in net proceeds for the full PIPE transaction.
One-year Discretionary Panel Monitor effective August 17, 2026; any new noncompliance may lead to a Delist Determination Letter.
Review of the decision may be requested within 15 calendar days, subject to a $15,000 fee.
DexCom named Jereme Sylvain, its executive vice president and chief financial officer, to also serve as chief operating officer, effective September 14, 2026, with oversight of global operations and quality teams. His new offer letter sets a base salary of $767,000 and a target bonus of 75% of base salary.
Sylvain keeps his CFO role and adds the COO title, effective September 14, 2026
Base salary of $767,000; annual target bonus equal to 75% of base salary
Offer letter dated September 11, 2026; a copy will be filed with the 10-Q for the quarter ended September 30, 2026
CEO Jake Leach said Sylvain will help the company scale more effectively
On September 8, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered an Amended and Restated Definitive Merger Agreement that replaces the existing agreement in its entirety. The parties set a fixed closing valuation of $2.85 billion for Power Analytics, replacing the prior $1.0 billion target and $300 million floor. Completion depends on conditions including shareholder approval, an acquisition of APQC Inc, and a minimum cash condition, so the deal has not closed.
Amended and Restated Definitive Merger Agreement dated September 8, 2026, replacing the Existing Agreement from April 29, 2026.
Closing valuation of $2.85 billion, replacing the $1.0 billion target valuation and $300 million floor valuation.
Merger Consideration capped at 265,116,279 Domesticated DMAA Common Shares, based on a Reference Price of at least $10.75.
Closing requires shareholder approval, completion of the APQC Acquisition and Available Closing Cash of at least $15 million.
Firefly Neuroscience's board terminated Chief Financial Officer Paul Krzywicki on September 8, 2026, effective September 24, 2026, and stated the decision was not the result of any disagreement over the company's operations, policies or practices. The company also appointed Jessica Paz as Chief Accounting Officer, with an annual base salary of $215,000 and a stock option for 50,000 shares. The filing does not name a successor CFO.
Board terminated CFO Paul Krzywicki on September 8, 2026, effective September 24, 2026
Termination was stated to be unrelated to any disagreement on operations, policies or practices
Jessica Paz employed as Chief Accounting Officer effective September 8, 2026, at $215,000 annual base salary
Paz received a stock option for 50,000 shares, vesting over four years with 25% after the first anniversary
Crown Castle said CFO Sunit Patel will retire effective March 31, 2027, and that its board intends to appoint EVP and Chief Commercial Officer Kristoffer Hinson as CFO effective April 1, 2027. COO Cathy Piche will step down from her COO role on September 23, 2026, serve as a special advisor, and leave the company on February 22, 2027, with a search for her successor underway. The changes affect two senior executive roles, and no compensation terms for Hinson have been set yet.
Sunit Patel retires as EVP and CFO effective March 31, 2027, after the 2026 Form 10-K is filed.
Kristoffer Hinson, currently EVP and Chief Commercial Officer, is intended to become EVP and CFO effective April 1, 2027.
Cathy Piche leaves the COO role September 23, 2026, serves as special advisor, and departs February 22, 2027.
Hinson's compensation arrangements have not been determined; any required changes will be disclosed by amendment to this 8-K.
Health Catalyst appointed Tami Reller as a Class III director, effective October 1, 2026, expanding the board from six to seven members. She will also chair the Audit Committee and join the Compensation Committee. The company's press release also states that Simeon Kohl was named Chief Executive Officer and President, effective September 14, 2026.
Tami Reller appointed to the board effective October 1, 2026, filling a newly created seat
Board expands from six to seven directors, effective October 1, 2026
Reller replaces Justin Spencer as Audit Committee chair; Spencer remains on the committee
Press release states Simeon Kohl was named CEO and President effective September 14, 2026
Lululemon appointed Heidi O'Neill as chief executive officer and as a member of its board on September 8, 2026, ending the interim co-CEO roles of Meghan Frank and Andre Maestrini. The same day, the board adopted bylaw amendments covering stockholder nominations, meeting procedures and emergency operations, which shareholders may wish to review in the filed bylaws.
Heidi O'Neill began service as CEO and joined the board on September 8, 2026; the board increased from 11 to 12 members
Meghan Frank and Andre Maestrini ceased serving as interim co-CEOs as of September 8, 2026
Bylaws amended September 8, 2026, effective immediately, to update stockholder nomination and proposal procedures for universal proxy cards
A new Article XIII adds emergency bylaws for emergencies or disasters; full text filed as Exhibit 3.1
Magnolia Oil & Gas completed its acquisition of WildFire Energy I LLC on September 10, 2026. The purchase price combined $2,570 million in cash, subject to final customary adjustments, 32,203,000 shares of Magnolia common stock, and the assumption of WildFire's $600.0 million 7.500% Senior Notes due 2029. The filing states that the share issuance was made under a Securities Act exemption and that resale registration rights were granted to the seller.
Acquisition completed September 10, 2026, with cash consideration of $2,570 million subject to final customary adjustments.
Equity consideration of 32,203,000 shares of common stock issued to seller WildFire Energy I LLC, with a 30-day lock-up on those shares.
Magnolia assumed the $600.0 million 7.500% Senior Notes due 2029, which mature October 15, 2029.
Magnolia Midstream LLC became a guarantor of Magnolia's 6.875% Senior Notes due 2032 and 6.625% Senior Notes due 2034.
Sionna Therapeutics said its Board approved a restructuring on September 9, 2026, that cuts about 46% of its workforce and winds down the SION-719 add-on program, with aggregate charges currently estimated at about $6.4 million. The company said the changes are meant to focus resources on the SION-451 and SION-2222 dual combination and extend its cash runway into the second half of 2029. Its Chief Business Officer's employment is ending, and the company is repricing employee stock options.
Restructuring charges are estimated at about $6.4 million, including $5.3 million in employee severance and other post-employment benefits, $0.7 million in SION-719 contract close-out costs and $0.4 million in stock-based compensation.
Workforce reduction and vendor wind-down are expected to be substantially complete by the end of the third quarter of 2026.
The company had about $268.3 million in cash, cash equivalents and marketable securities at the end of Q2 2026, and expects its runway to extend into the second half of 2029.
Chief Business Officer Caroline Stark Beer's employment ends September 15, 2026; option repricing takes effect September 17, 2026.
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
Upfront cash consideration of $150 million, subject to customary purchase price adjustments
Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
Merger agreement dated September 10, 2026; closing completed September 14, 2026
Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not achieve its primary efficacy endpoint. Johnson & Johnson, which develops the drug under a global license and development agreement, is still evaluating the data, including prespecified exploratory endpoints, to decide next steps.
Trial did not meet its primary efficacy endpoint, measured as change from baseline in MADRS total score at Day 5 versus placebo.
JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.
Johnson & Johnson continues to assess the totality and clinical relevance of the findings to inform next steps for the drug.
Analyses of the data, including prespecified exploratory endpoints, are ongoing.
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, up 60% from the prior year period, and raised its FY27 revenue guidance to $141 million from $137 million. The GAAP net loss widened to $44.1 million from $25.8 million, so revenue growth came with larger losses for shareholders.
Revenue was $31.0 million for the quarter ended July 31, 2026, up 60% from the prior year period; gross margin was 56.5% versus 45.7%.
GAAP net loss was $44.1 million, or $0.75 per share, compared with $25.8 million, or $0.50 per share, a year earlier.
FY27 revenue guidance was increased to $141 million, growth of 48% over FY26, from prior guidance of $137 million.
Cash, cash equivalents and investments totaled $244.7 million as of July 31, 2026; total liquidity was about $320 million including committed unused term loan availability.
On September 14, 2026, Ondas Inc. completed its acquisition of Gate Technologies Ltd., an Israeli maker of electronic safe-and-arm devices, and Bron Technologies sp. z.o.o., a Polish manufacturer. The 8-K lists $105.0 million in cash and 10,689,655 shares of common stock at closing, plus a $25 million working capital adjustment, with up to $185 million in earn-out payments over two years. Ondas expects the acquired business to contribute more than $130 million of Adjusted EBITDA through 2028, and the new shares can be resold only within volume limits set by a registration rights agreement.
Closing payment of $105.0 million in cash and 10,689,655 shares of common stock, plus a $25 million working capital adjustment
About $22.5 million more to be issued within nine months of the Closing Date, subject to post-closing obligations of the Indemnifying Parties
Up to $185 million in contingent earn-out payments over two years after closing, payable in common stock per the 8-K
Shareholders may sell no more than 15% of average daily trading volume in any single trading day under the registration rights agreement
The Baldwin Insurance Group agreed to be acquired by an entity formed by Sequence Holdings and DFO Management, the Dell family investment office, in an all-cash deal. Shareholders would receive $32.50 per share, and the transaction implies a total enterprise value of about $7.7 billion, including about $3.1 billion of net debt. The deal requires shareholder and regulatory approvals and is expected to close in Q1 2027, after which Baldwin shares would stop trading on Nasdaq.
Shareholders to receive $32.50 per share in cash, a premium of about 88% to the unaffected closing price on June 17, 2026
Equity purchase price of about $4.6 billion and total enterprise value of about $7.7 billion, implying about 20x trailing-twelve-month Adjusted EBITDA of about $396 million
Expected close in Q1 2027, subject to shareholder approval, regulatory approvals and other customary conditions
Shares would be delisted from Nasdaq and deregistered under the Exchange Act after the effective time
The 35-day go-shop period for Bowman Consulting's merger with entities affiliated with Bernhard Capital Partners expired at 5:00 p.m. Eastern Time on September 13, 2026, with no alternative proposals received. Under the all-cash deal at $43.00 per share, the company is now subject to customary no-shop restrictions, and the transaction is still expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals.
Go-shop period expired at 5:00 p.m. ET on September 13, 2026; no proposals were received before expiration.
The company contacted 76 potentially interested parties and entered confidentiality agreements with 8 of them.
Bernhard will acquire Bowman for $43.00 per share in cash, an enterprise value of about $1.0 billion and a premium of about 58% to the unaffected August 7, 2026 closing price.
The transaction is expected to close in the fourth quarter of calendar 2026, subject to stockholder approval and regulatory approvals.
Definium Therapeutics announced positive topline results from Panorama, its second Phase 3 study of DT120 ODT in generalized anxiety disorder, meeting its primary endpoint and all key secondary endpoints. The filing also posted a presentation on the company website, and the company plans a pre-NDA meeting with the FDA in 4Q 2026 and an NDA filing in 1H 2027.
Primary endpoint met: placebo-adjusted HAM-A change of 5.1 points at Week 12 for the 100 µg dose (p<0.0001), with 96 participants in the 100 µg group and 97 on placebo
Company reports the drug was generally well tolerated, with no drug-related serious adverse events and no new safety signals identified
Pre-NDA meeting scheduled for 4Q 2026; NDA filing anticipated in 1H 2027
Webcast to review results held at 8:00 a.m. EDT on September 14, 2026
Thryv, Inc., a wholly owned subsidiary of Thryv Holdings, agreed on September 12, 2026 to sell its Yellow and White Pages print directories business in the US, Australia and New Zealand to an affiliate of Carolwood, L.P. for $142 million in cash, subject to customary adjustments. The company said it intends to use the net proceeds to repay debt and other liabilities. The filing does not state the business's revenue or profit, so shareholders cannot yet judge the effect on earnings.
Cash purchase price of $142 million, subject to customary purchase price adjustments
Internet Yellow Pages and other online properties are excluded and will be retained by Thryv
Closing expected in the fourth quarter of 2026, subject to customary closing conditions
After closing, Thryv will provide certain services under a management services agreement
On September 11, 2026, Scholar Rock Holding Corporation announced that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years of age and older who are receiving an SMN2-targeted treatment. The company said the U.S. commercial launch is underway, with product available to ship in the coming days, and it received a Rare Pediatric Disease Priority Review Voucher with the approval.
Phase 3 SAPPHIRE study: 2.2-point HFMSE motor function improvement vs. placebo at one year (nominal p=0.0121)
34.2% of ISEMBYLD-treated patients showed a 3-point or greater HFMSE increase vs. 13.5% on placebo
Fractures occurred in 9% of ISEMBYLD 10 mg/kg patients vs. 2% on placebo; the label notes an increased fracture risk
Management webcast and conference call on September 14, 2026, at 8:00 a.m. ET; cash and securities were $492 million as of June 30, 2026
Perdoceo Education agreed on September 14, 2026 to acquire 100% of South University Savannah, LLC from South University – Member, Inc., with a $150 million initial cash payment at closing before adjustments. The company said it expects to complete the deal as early as April 2027 and that it would be immediately accretive to adjusted operating income beginning in 2027, and it reaffirmed its fiscal 2026 adjusted operating income outlook of $258 million to $263 million.
Cash consideration: about $150 million at closing (subject to adjustments), $18 million deferred over 24 months, and up to $56 million in earn-outs tied to EBITDA for fiscal 2027 through 2029
South reported unaudited 2025 revenues of approximately $291 million and adjusted operating income of approximately $34 million
Closing is expected as early as April 2027, subject to regulatory and accreditor approvals; either party may terminate if closing has not occurred by July 9, 2027, with a termination fee of up to $20 million
Perdoceo reaffirmed its full-year 2026 adjusted operating income outlook of $258 million to $263 million
On September 10, 2026, AirJoule Technologies, a subsidiary of AirJoule Technologies Corporation, acquired all equity of Bitsink LLC, a South Carolina maker of cooling, power distribution and racking infrastructure for data centers. The upfront price was $18 million in cash, subject to adjustments, plus 1,859,504 shares of Class A common stock, with up to $40 million more in stock payable if 2027 to 2029 revenue targets are met.
Upfront consideration: $18 million in cash (subject to certain adjustments) and 1,859,504 shares of Class A common stock issued to seller Stanislav Dyshko.
Earnout: up to $40 million payable in Class A common stock if revenue targets are achieved during 2027 through 2029; maximum of 8,264,463 additional shares.
AirJoule Technologies had $45 million of cash on the balance sheet on August 31, 2026, before the transaction.
The press release says Bitsink had cumulative revenue of approximately $11 million across 2024 and 2025.
Flowserve said CFO Amy Schwetz, who also serves as interim Chief Accounting Officer, is leaving to join another publicly traded company, with her last day on September 30, 2026. Brian Ezzell, the company's current Vice President of FP&A, Treasurer and Investor Relations, will take over as CFO and interim Chief Accounting Officer on October 1, 2026. The company said there is no change to its full-year 2026 guidance, and the filing states that Schwetz's departure is not related to any financial or accounting issue.
Amy Schwetz's last day as CFO and interim Chief Accounting Officer is September 30, 2026
Brian Ezzell, 44, becomes CFO and interim Chief Accounting Officer effective October 1, 2026, and has held his current role since October 2024
Ezzell's annual base salary is $625,000, with a 75% target annual incentive and a $1,600,000 target long-term incentive award beginning in 2027
Flowserve expects no change to its previously announced full-year 2026 guidance
Hain Celestial agreed on September 12, 2026 to sell its International business in the UK, Ireland and Europe to affiliates of AURELIUS, with estimated net proceeds of $305 million to $310 million to be used to reduce debt. Closing depends on regulatory approvals and a credit agreement amendment by October 12, 2026, which the company says it is still negotiating with lenders. The same day it reported fiscal fourth-quarter net sales down 28% to $263 million, with a narrower net loss of $62 million.
Gross sale price of £233.0 million plus an estimated £5.5 million locked box amount, about $323.2 million in total; expected net cash proceeds of $305 million to $310 million
Closing requires a credit agreement amendment by October 12, 2026 extending the December 22, 2026 maturity by at least nine months; the purchasers may terminate if it is not obtained
Expected closing in the fiscal second quarter ending December 31, 2026
Fiscal Q4 2026 net sales $263 million, down 28%; net loss $62 million versus $273 million; loss per diluted share $0.68 versus $3.06
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.